Tocilizumab-bavi bulk supplier for pharma manufacturers

Tocilizumab-Bavi 80 mg/4ml Suppliers & Bulk Manufacturers

Available Forms: Intravenous infusion

Available Strengths: 80 mg/4ml

Reference Brands: Actemra; Tofidence - biosimilar to Actemra (tocilizumab).

Tofidence, a biosimilar to Actemra (tocilizumab), blocks interleukin-6 (IL-6) receptors, reducing inflammation and cytokine activity. It effectively treats rheumatoid arthritis, juvenile idiopathic arthritis, and cytokine storm. Benefits include similar efficacy, lower costs, increased accessibility, and improved management of inflammatory and autoimmune diseases when used under medical supervision.

Get Enquiry / Request Bulk Quote

Quick Response Guaranteed | Verified Suppliers

Product Description:

Ofidence, a biosimilar to Actemra (tocilizumab), is regulated in the EU and US, supported by dossiers demonstrating biosimilarity, safety, efficacy, and manufacturing quality according to GMP standards. In the US, FDA approval involves extensive comparability data, clinical validation, and safety assessments. In the EU, CE marking confirms conformity with MDR standards. These biosimilars undergo validation, stability testing, and audits, with comprehensive documentation including biosimilarity, clinical data, safety profiles, and manufacturing practices. For licensing procedures, approved dossiers, and regulatory updates, visit Pharmatradz. Ensuring compliance guarantees access to affordable, high-quality biosimilar therapies for inflammatory and autoimmune diseases globally.

Tocilizumab-Bavi — third party manufacturing & bulk supply

Tocilizumab-Bavi 80 mg/4ml is available through PharmaTradz for wholesale and bulk supply as well as on a third party (contract) manufacturing basis. Buyers sourcing this product generally take one of three routes:

Wholesale / bulk supply Stock or scheduled supply from an existing manufacturer. The fastest route where the product is already registered in your market.

Third party manufacturing Manufactured to your specification and packed under your own brand and label — suits distributors and brand owners building a portfolio in their market.

Dossier licensing Where a CTD, EU-CTD or ACTD dossier exists it can often be licensed for filing in your name, compressing market entry from years to months.

Indicative minimum order quantity

Tocilizumab-Bavi is supplied as Intravenous infusion — an injectable dosage form, so the indicative MOQ is 50,000 units. Actual MOQ is confirmed by the allocated manufacturer against your pack presentation and destination market. See full supply terms for dossier formats, market availability and shelf life.

Manufacturers of Tocilizumab-Bavi listed on PharmaTradz hold site-level approvals across WHO-GMP, EU-GMP, USFDA, ANVISA and TGA, verified at onboarding.

Request a quote for Tocilizumab-Bavi →

Back to Listing

Frequently Asked Questions

Tocilizumab-bavi is listed as Intravenous infusion in 80 mg/4ml. Further strengths and pack presentations are confirmed with the manufacturer at RFQ stage.

Tocilizumab-bavi is referenced against Actemra; Tofidence - biosimilar to Actemra (tocilizumab).. Reference brands are shown for identification only and remain the property of their respective trademark owners.